Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of Directors
Senior management
Our history
Research and development
Technology platform
Therapeutic areas
Pipeline
Scientific papers and presentations
Partnering
Our approach
Our partnerships
Investors
Share information
Events & Presentations
Financial reports
Financial calendar
Shareholder meetings
Shareholder information
Analyst coverage
Corporate governance
ESG
Newsroom
Press Releases
Image library
Glossary
Careers
Search
Research and development
Scientific papers and presentations
Sharing our discoveries and developments in our tireless pursuit of breakthrough therapies
Newest first
Oldest first
Posters & Papers
Presentations
Search
Reset
30/05/2025
ASCO 2025: Introduction of Neoantigen-Specific Immune Responses by VB10.NEO in Combination with Atezolizumab in Heavily Pretreated Patients with Advanced Solid Tumors: Final Analysis of the Phase 1b VB-N-02 Trial
30/05/2025
ASCO 2025: Integrative analysis of VB10.16 and atezolizumab in advanced HPV16-positive cervical cancer: Linking biomarker insights to clinical outcomes
14/05/2025
CIMT 2025: DNA-encoded individualized neoantigen vaccines elicit durable and functional immune responses
27/02/2025
ASIT 2025: APC-Targeted Vaccines Deliver Antigen Specific Immune Tolerance
27/02/2025
ASIT 2025: APC-Targeted Vaccines Deliver Antigen Specific Immune Tolerance in Mouse Models of Autoimmune Disease
Pages:
1
2
3
4
5
6
7
8
9
10
11
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
